Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442278 | 0.87 | APOBEC3G (0.73) | APOBEC3GSLC6A4SLC6A2LDHASLC6A3 | |
| SCHEMBL5520107 | 0.80 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3IFNAR1LMNA | |
| SCHEMBL7559665 | 0.78 | APOBEC3G (0.59) | APOBEC3GSLC6A4SLC6A2LDHASLC6A3 | |
| Bipenamol SCHEMBL29444593 | 0.78 | APOBEC3G (0.59) | APOBEC3GSLC6A4SLC6A2LDHASLC6A3 | |
| Bipenamol SCHEMBL91233 | 0.78 | APOBEC3G (0.59) | APOBEC3GSLC6A4SLC6A2LDHASLC6A3 | |
| SCHEMBL4448364 | 0.78 | APOBEC3G (0.59) | APOBEC3GSLC6A4SLC6A2LDHASLC6A3 | |
| SCHEMBL73812 | 0.78 | APOBEC3G (0.59) | APOBEC3GSLC6A4SLC6A2LDHASLC6A3 | |
| Bipenamol SCHEMBL30791275 | 0.76 | APOBEC3G (0.57) | APOBEC3GSLC6A4SLC6A2LDHASLC6A3 | |
| SCHEMBL13579946 | 0.76 | APOBEC3G (0.57) | APOBEC3GSLC6A4SLC6A2SLC6A3IFNAR1 | |
| Bipenamol SCHEMBL636892 | 0.76 | APOBEC3G (0.57) | APOBEC3GSLC6A4SLC6A2LDHASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | claimed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | claimed |
| EP-1633702-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-15 | — | — | EP | claimed |
| WO-2004106289-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-09 | — | — | WO | claimed |
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CHEMRX ADVANCED TECHNOLOGIES, INC. | 2002-08-01 | — | — | US | claimed |
| WO-2001040193-A1 | METHOD FOR THE SYNTHESIS OF PYRAZOLINES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| EP-0800513-A1 | OPIATE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1997-10-15 | — | — | EP | claimed |
| US-5605932-A | Opiate receptor ligands | CHIRON CORPORATION (US) | 1997-02-25 | — | — | US | claimed |
| US-5536868-A | Opiate receptor ligands | CHIRON CORPORATION (US) | 1996-07-16 | — | — | US | claimed |
| WO-1996020921-A1 | OPIATE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1996-07-11 | — | — | WO | claimed |
| US-5481020-A | Opiate receptor ligands | CHIRON CORPORATION (US) | 1996-01-02 | — | — | US | claimed |
| EP-1975153-A2 | Protease inhibitors | Prozymex A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| EP-1633702-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-15 | — | — | EP | disclosed |
| EP-0800513-A1 | OPIATE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1997-10-15 | — | — | EP | disclosed |
| US-5605932-A | Opiate receptor ligands | CHIRON CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| US-5536868-A | Opiate receptor ligands | CHIRON CORPORATION (US) | 1996-07-16 | — | — | US | disclosed |
| WO-1996020921-A1 | OPIATE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1996-07-11 | — | — | WO | disclosed |
| US-5481020-A | Opiate receptor ligands | CHIRON CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CYP2F1, CYP2E1, CYP3A7 | APOBEC3G 3248/4885SLC6A4 2474/4885SLC6A2 3462/4885 |
| US-20070155803-A1 | Protease inhibitors | DPP7, DPP9, DPP3 | APOBEC3G 990/4885SLC6A4 3251/4885SLC6A2 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.